Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

2.88USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$2.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
108,867
52-wk High
$5.10
52-wk Low
$2.03

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.45
Market Cap(Mil.): $165.38
Shares Outstanding(Mil.): 31.35
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 30.48 33.71
EPS (TTM): -0.89 -- --
ROI: -68.80 14.98 14.48
ROE: -79.58 16.31 15.99

BRIEF-Adamis Pharmaceuticals’ Commercial Partner Launches Symjepi (Epinephrine) In The US

* ADAMIS’ COMMERCIAL PARTNER LAUNCHES SYMJEPI™ (EPINEPHRINE) IN THE US

Jan 16 2019

Swiss stocks - Factors to watch on Dec. 7

ZURICH/BERLIN, Dec 7 The Swiss blue-chip SMI was seen opening 1.2 percent higher at 8,765 points on Friday, according to premarket indications by bank Julius Baer .

Dec 07 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

Dec 06 2018

BRIEF-Adamis Pharmaceuticals Provides Update On Symjepi's U.S. Launch

* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON THE U.S. LAUNCH OF SYMJEPI

Dec 06 2018

BRIEF-Adamis Pharmaceuticals Says Working With Sandoz To Prepare Symjepi Launch

* ADAMIS PHARMACEUTICALS - WORKING CLOSELY WITH SANDOZ TO PREPARE A SUCCESSFUL LAUNCH FOR SYMJEPI

Aug 27 2018

Earnings vs. Estimates